CN113009155A - Fgf20在制备诊断溃疡性结肠炎试剂的应用 - Google Patents

Fgf20在制备诊断溃疡性结肠炎试剂的应用 Download PDF

Info

Publication number
CN113009155A
CN113009155A CN202110254746.5A CN202110254746A CN113009155A CN 113009155 A CN113009155 A CN 113009155A CN 202110254746 A CN202110254746 A CN 202110254746A CN 113009155 A CN113009155 A CN 113009155A
Authority
CN
China
Prior art keywords
fgf20
ulcerative colitis
reagent
growth factor
pdgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110254746.5A
Other languages
English (en)
Other versions
CN113009155B (zh
Inventor
龚方华
张宏宇
黄鹏
孔晓霞
王德仲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cixi Institute Of Biomedicine Wenzhou Medical University
Original Assignee
Cixi Institute Of Biomedicine Wenzhou Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cixi Institute Of Biomedicine Wenzhou Medical University filed Critical Cixi Institute Of Biomedicine Wenzhou Medical University
Priority to CN202110254746.5A priority Critical patent/CN113009155B/zh
Publication of CN113009155A publication Critical patent/CN113009155A/zh
Application granted granted Critical
Publication of CN113009155B publication Critical patent/CN113009155B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

本发明公开了FGF20在制备诊断溃疡性结肠炎试剂的应用。本发明是首次发现FGF20，特别是FGF20、血小板衍生生长因子(PDGF)‑BB和纤维蛋白原FIB的组合能够作为诊断溃疡性结肠炎，能够作为溃疡性结肠炎的初步诊断方案，具有较高的检测特异性。

Description

FGF20在制备诊断溃疡性结肠炎试剂的应用
技术领域
本发明属于医学检测领域，具体是FGF20在制备诊断溃疡性结肠炎试剂的应用。
背景技术
溃疡性结肠炎是一种消化系统疾病，目前病因尚不明确。顾名思义，该病的主要发作部位是结肠，但偶尔会在回肠发作。溃疡性结肠炎是一种病因尚不十分清楚的结肠和直肠慢性非特异性炎症性疾病，病变局限于大肠黏膜及黏膜下层。病变多位于乙状结肠和直肠，也可延伸至降结肠，甚至整个结肠。病程漫长，常反复发作。本病见于任何年龄，但20～30岁最多见。
随着科技进步，UC的诊断和治疗不断发展。目前用于UC临床诊断的的方法主要为内镜、组织病理学和血液检查。但是许多患者因病情严重导致肠腔狭窄、虚弱等情况，难以耐受内镜检查，使得临床诊断和病情严重程度评估受到巨大限制。血液检查包括血沉、C-反应蛋白、内毒素等指标，但是由于上述指标缺乏特异性，导致UC难以与其他消化道疾病(如：淋巴瘤、肠结核、缺血性肠炎等)相鉴别，易引起误诊，延误治疗。此外，由于发病机制尚不明确，目前UC的临床治疗亦面临巨大挑战。因此，探索UC的发病机制，寻找特异性的UC诊断标志物和治疗靶点，对我国UC的临床诊治极其重要。
溃疡性结肠炎的诊断上主要依靠纤维结肠镜检，因为90％～95％患者直肠和乙状结肠受累，因此事实上通过纤维乙状结肠镜检已能明确诊断。镜检中可看到充血、水肿的黏膜，脆而易出血。在进展性病例中可看到溃疡，周围有隆起的肉芽组织和水肿的黏膜，貌似息肉样，或可称为假息肉形成。在慢性进展性病例中直肠和乙状结肠腔可明显缩小，为明确病变范围，还是应用纤维结肠镜作全结肠检查，同时作多处活组织检查以便与克隆结肠炎鉴别。
气钡灌肠双重对比造影也是一项有助诊断的检查，特别有助于确定病变范围和严重程度。在钡灌造影中可见到结肠袋形消失，肠壁不规则，假息肉形成以及肠腔变细、僵直。虽然钡剂灌肠检查是有价值的，但检查时应谨慎，避免肠道清洁准备，因为它可使结肠炎恶化。无腹泻的病例检查前给3天流质饮食即可。有腹部征象的病例忌作钡剂灌肠检查，而应作腹部X线平片观察有无中毒性巨结肠、结肠扩张以及膈下游离气体征象。
FGF20(成纤维细胞生长因子20)成纤维细胞生长因子家族的一名新成员,其氨基酸序列与其他成员之间具有不同程度的同源性.FGF-20仅在成年人脑组织,尤其是小脑组织有特异性表达,在一些肿瘤细胞株中也有一定量表达。据文献报道，FGF20在结直肠癌中的具有高表达，其可能在结直肠癌的发生发展中起关键作用。但是，文献尚未报道FGF20在溃疡性结肠炎中具有高表达，特别是通过检测血清中FGF20就可以有助于对溃疡性结肠炎进行初步诊断尚未被文献所公开或者报道。
发明内容
本发明的目的在于提供一种溃疡性结肠炎诊断试剂，以解决上述背景技术中提出的问题。
为实现上述目的，本发明提供如下技术方案：
本发明一方面涉及成纤维细胞生长因子20在制备诊断溃疡性结肠炎试剂中的应用。
在本发明的另一个优选实施方式中，成纤维细胞生长因子20、血小板衍生生长因子(PDGF)-BB和纤维蛋白原FIB同时在制备诊断溃疡性结肠炎试剂中的应用。
本发明另一方面还涉及一种诊断溃疡性结肠炎的诊断试剂，其包括检测血清中成纤维细胞生长因子20、血小板衍生生长因子(PDGF)-BB和纤维蛋白原FIB浓度的试剂。
在本发明的一个优选实施方式中，所述的检测血清中成纤维细胞生长因子20和血小板衍生生长因子(PDGF)-BB浓度的试剂为ELISA试剂盒；所述检测血清中纤维蛋白原FIB为火箭电泳法检测试剂盒。
本发明另一方面还涉及一种诊断溃疡性结肠炎的生物标志物，其包括成纤维细胞生长因子20、血小板衍生生长因子(PDGF)-BB和纤维蛋白原FIB。
有益效果
与现有技术相比，本发明的有益效果是：
本发明是首次发现成纤维细胞生长因子20(FGF20)，特别是FGF20、血小板衍生生长因子(PDGF)-BB和纤维蛋白原FIB的组合能够作为诊断溃疡性结肠炎，能够作为溃疡性结肠炎的初步诊断方案，具有较高的检测特异性。。
附图说明
图1为示出溃疡性结肠炎患者与健康人群的血清中FGF20的浓度比较的图。
图2为示出溃疡性结肠炎患者与健康人群的血清中PDGF-BB的浓度比较的图。
图3为示出溃疡性结肠炎患者与健康人群的血清中纤维蛋白原FIB的浓度比较的图。
具体实施方式
为了进一步理解本发明，下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
如无特殊说明，本发明实施例中所涉及的试剂均为市售产品，均可以通过商业渠道购买获得。
实施例1
样品采集
38溃疡性结肠炎患者均来自温州医科大学附属第三医院，患者年龄为20-30岁，平均年龄为25.9岁，男20例，女18例。另采集健康人群20例的全血样本，平均年龄26.3岁，男10例，女10例。
全血标本,室温放置小时内3000g离心5分钟,吸取上清液转移至无菌EP管，分装后于-80℃保存至检测前。
试验方法与结果
采用ELISA试剂盒方法检测血清中FGF20和PDGF-BB含量；纤维蛋白原FIB按常规火箭电泳法进行检测。人成纤维细胞生长因子20(FGF20)ELISA检测试剂盒来自江莱生物，其操作按照试剂盒说明书进行。PDGF-BB ELISA试剂盒来自合肥知恩生物，其操作按照试剂盒说明书进行。
检测结果如图1～3所示，结果为：溃疡性结肠炎患者的FGF20、PDGF-BB和纤维蛋白原FIB都显著高于健康人群，表明在溃疡性结肠炎患者中，FGF20、PDGF-BB和纤维蛋白原FIB的组合可以作为诊断标志物。
实施例2
选取2020年5-10月温州医科大学附属第一医院肛肠科的溃疡性结肠炎的100例，基于血清中FGF20、PDGF-BB和纤维蛋白原FIB的含量确定AUC值，结果如下表1所示。
表1：诊断AUC值
标志物 AUC值
FGF20 0.705
PDGF-BB 0.619
纤维蛋白原FIB 0.623
FGF20+PDGF-BB 0.763
FGF20+纤维蛋白原FIB 0.732
PDGF-BB+纤维蛋白原FIB 0.658
FGF20+PDGF-BB+纤维蛋白原FIB 0.862
结果显示，FGF20单独作为溃疡性结肠炎诊断标志物的AUC值为0.705。而FGF20、PDGF-BB和纤维蛋白原FIB联合诊断的AUC值为0.862，应用于溃疡性结肠炎的诊断具有较高的准确性。
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。

Claims (5)

1.成纤维细胞生长因子20(FGF20)在制备诊断溃疡性结肠炎试剂中的应用。
2.成纤维细胞生长因子20(FGF20)、血小板衍生生长因子(PDGF)-BB和纤维蛋白原FIB同时在制备诊断溃疡性结肠炎试剂中的应用。
3.一种诊断溃疡性结肠炎的诊断试剂，其包括检测血清中成纤维细胞生长因子20(FGF20)、PDGF-BB和纤维蛋白原FIB浓度的试剂。
4.根据权利要求3所述的诊断试剂，所述的检测血清中成纤维细胞生长因子20(FGF20)和PDGF-BB浓度的试剂为ELISA试剂盒；所述检测血清中纤维蛋白原FIB为火箭电泳法检测试剂盒。
5.一种诊断溃疡性结肠炎的生物标志物，其包括成纤维细胞生长因子20(FGF20)、PDGF-BB和纤维蛋白原FIB。
CN202110254746.5A 2021-03-05 2021-03-05 Fgf20在制备诊断溃疡性结肠炎试剂的应用 Active CN113009155B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110254746.5A CN113009155B (zh) 2021-03-05 2021-03-05 Fgf20在制备诊断溃疡性结肠炎试剂的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110254746.5A CN113009155B (zh) 2021-03-05 2021-03-05 Fgf20在制备诊断溃疡性结肠炎试剂的应用

Publications (2)

Publication Number Publication Date
CN113009155A true CN113009155A (zh) 2021-06-22
CN113009155B CN113009155B (zh) 2022-03-25

Family

ID=76402715

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110254746.5A Active CN113009155B (zh) 2021-03-05 2021-03-05 Fgf20在制备诊断溃疡性结肠炎试剂的应用

Country Status (1)

Country Link
CN (1) CN113009155B (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
US20110207663A1 (en) * 2008-06-16 2011-08-25 University Of Rochester Fibroblast growth factor (fgf) analogs and uses thereof
CN104293821A (zh) * 2014-08-13 2015-01-21 温州医科大学 重组人成纤维细胞生长因子-20的基因克隆、表达及应用
US20170335395A1 (en) * 2014-10-27 2017-11-23 The Trustees Of The University Of Pennsylvania A parkinson's disease diagnostic biomarker panel
CN110062764A (zh) * 2016-12-05 2019-07-26 儿童医院医学中心 结肠类器官及其制备和使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
US20110207663A1 (en) * 2008-06-16 2011-08-25 University Of Rochester Fibroblast growth factor (fgf) analogs and uses thereof
CN104293821A (zh) * 2014-08-13 2015-01-21 温州医科大学 重组人成纤维细胞生长因子-20的基因克隆、表达及应用
US20170335395A1 (en) * 2014-10-27 2017-11-23 The Trustees Of The University Of Pennsylvania A parkinson's disease diagnostic biomarker panel
CN110062764A (zh) * 2016-12-05 2019-07-26 儿童医院医学中心 结肠类器官及其制备和使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JEFFERS M 等: "A novel human fibroblast growth factor treats experimental intestinal inflammation", 《GASTROENTEROLOGY》 *
夏秀秀等: "FGF21 与溃疡性结肠炎小鼠相关性研究", 《现代畜牧兽医》 *
王大秀等: "血小板、纤维蛋白原、D-二聚体与溃疡性结肠炎相关性的研究", 《胃肠病学》 *
赵央等: "成纤维细胞生长因子２０研究进展", 《中国生物工程杂志》 *

Also Published As

Publication number Publication date
CN113009155B (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
WO2019233102A1 (zh) 用于结直肠癌诊断、检测或筛查的引物和探针组
EP2210942B1 (en) Gene associated with liver cancer, and method for determination of the risk of acquiring liver cancer
CN109557311B (zh) 结直肠癌诊断标志物及结直肠癌的检测产品及其应用
Wang et al. Evaluating the clinical performance of a dual-target stool DNA test for colorectal cancer detection
CN113009155B (zh) Fgf20在制备诊断溃疡性结肠炎试剂的应用
SCHREINER The clinical and histologic spectrum of pyelonephritis
Shahsavari et al. Expanding beyond endoscopy: A review of non-invasive modalities in Barrett’s esophagus screening and surveillance
CN108342487A (zh) 基于血清exosomallncRNAs的食管癌诊断特异性表达图谱及检测分析系统
Antonioli Pediatric inflammatory bowel disease
CN114150048B (zh) 一种用于IgA肾病检测的系统、方法及方法的建立
CN110257502A (zh) 肠无神经节细胞症血浆外泌体诊断标志物及其应用
Halme et al. Concentrations of pancreatic secretory trypsin inhibitor (PSTI), acute phase proteins, and neopterin in Crohn's disease. Comparison with clinical disease activity and endoscopical findings
RU2827128C1 (ru) Способ дифференциального определения вероятности наличия воспалительных заболеваний кишечника
CN108486237B (zh) 基于kras和ndrg4基因以及血红蛋白确定结直肠肿瘤细胞的方法和系统
TWI690597B (zh) 泌尿上皮癌的檢測套組及檢測方法
US20230407403A1 (en) Method for assisting determination on suitability of esophageal cancer for endoscopic therapy, method for determining suitability of esophageal cancer for endoscopic therapy, method for collecting data for use in determination on suitability of esophageal cancer for endoscopic therapy, method for diagnosing suitability of esophageal cancer for endoscopic therapy, in vitro method for assisting determination on suitability of esophageal cancer for endoscopic therapy, ...
CN108676893A (zh) 用于检测大肠癌的生物标志物及其应用
Nicole et al. Preoperative Serum Vedolizumab Levels Do Not Impact Postoperative Outcomes in Inflammatory Bowel Disease (IBD): P-122
Nielce et al. Ileal pouch of ulcerative colitis patients exhibit impaired autophagy: P-121
CN114414806A (zh) 用于胆囊癌诊断的标志物及其应用
Soorya et al. Pseudopolyposis: A Manifestation of Isolated Upper Gastrointestinal Crohn's Disease: P-120
Nunez Ortiz et al. P322 Impact of the presence of Epstein–Barr virus in intestinal mucosa of inflammatory bowel disease patients
Zoltan et al. Comparison of the Expression of Metalloproteinases and Their Tissue Inhibitors in Ulcerative Colitis and Colon Diverticulitis: P-123
Costa-Moreira et al. Acute Colic Pseudo-obstruction as a Manifestation of Lead Intoxication in a Sacred Art Conservator: A Case Report: 1478
Murillo et al. A Ten-year Review of Peritoneal Tuberculosis in Children at a Government Tertiary Hospital

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant